Understanding the Market | BIOCYTOGEN-B rose over 5% in the morning, with a mid-term profit attributable to shareholders of HKD 47.999 million, highlighting the value of the company's gene editing technology

BIOCYTOGEN-B's stock price rose more than 5% in the morning, and as of the time of publication, it was up 4.83%, trading at HKD 24.76, with a transaction volume of HKD 7.4404 million. The company released its interim results for the period ending June 30, 2025, reporting revenue of RMB 621 million, a year-on-year increase of 51.3%; the profit attributable to shareholders was RMB 47.99 million, turning from a loss to a profit year-on-year. The company has established a dual-engine growth model based on gene editing technology, creating innovative animal models and antibody discovery businesses, forming competitive barriers, and continuously enhancing long-term growth value and investment attractiveness